Successful drug development often hinges on selecting the most suitable solid form as early as possible. Failure to do so can lead to significant challenges, including the emergence of undesirable polymorphs that pose risks to patient safety and result in substantial financial losses. By combining solid form techniques with physicochemical profiling, researchers can significantly reduce the risk of such failures.
Understanding the relationship between solid form properties and physicochemical characteristics is essential for optimizing drug development. Parallel solid form and physicochemical profiling provides valuable insights into a drug candidate’s potential for success, enabling focused development efforts and accelerating the selection of promising compounds. Through the integrated application of these disciplines, scientists can streamline development processes and increase the likelihood of bringing safe and effective therapies to market.
In this white paper, Veranova’s Associate Director, Pharmorphix® Solid Form & Particle Engeneering, Olana Couzins, discusses the importance of running both solid form and physicochemical disciplines in parallel.
